[ET Net News Agency, 10 November 2021] Ascletis Pharma Inc. (01672) announced the
approval of the Phase II clinical trial of ASC22 (Envafolimab) by China National Medical
Products Administration (NMPA) for the proposed new indication of immune
restoration/functional cure of human immunodeficiency virus 1 (HIV-1) infected patients.
ASC22 (Envafolimab) is a subcutaneously administered single domain antibody against
PD-L1 and has the potential to restore virus-specific immune responses in patients with
chronic viral infection. Immune restoration/functional cure in HIV-1 infected patients is
the second indication of ASC22 developed by Ascletis, in addition to functional cure of
chronic hepatitis B (CHB) patients. (RC)